PLGA-PEG-azide from PolySciTech used in development of decorated nanoparticle for cancer immunotherapy

 

Cancer cells and tumors typically apply a wide variety of strategies to evade the human immune system which makes treatment of them very difficult. Induction of a targeted immunoresponse against tumors and cancer cells can provide for a promising opportunity to leverage the power of the human immune system towards elimination of cancer. Researchers at Chinese Academy of Sciences, Jiangnan University, and Shenzhen University (China) used mPEG-PLGA (cat# AK102) and PLGA-PEG-N3 (cat# AI091) from PolySciTech (www.polyscitech.com) to create immunotherapy initiating nanoparticles by Pickering emulsion methodologies. This research holds promise to provide for improved therapies against cancer. Read more: Du, Yiqun, Tiantian Song, Jie Wu, Xiao-Dong Gao, Guanghui Ma, Yuchen Liu, and Yufei Xia. "Engineering mannosylated pickering emulsions for the targeted delivery of multicomponent vaccines." Biomaterials 280 (2022): 121313. https://www.sciencedirect.com/science/article/abs/pii/S0142961221006694

“Abstract: While research on cancer vaccines has made great strides in the field of immunotherapy, the targeted delivery of multiple effective components (rational-tailored antigens and adjuvants) remains a challenge. Here, we utilized the unique hierarchical structures of Pickering emulsions (particles, oil core, and water-oil interface) to develop mannosylated (M) Pickering emulsions (PE) that target antigen presenting cells and synergistically deliver antigenic peptides and the TLR9 agonist CpG (C) as an enhanced cancer vaccine (MPE-C). We chemically linked mannose residues to PLGA/PLAG-PEG nanoparticles and produced a dense array of mannose on the nanopatterned surface of Pickering emulsions, allowing for increased cellular targeting. Together with the inherent deformability of the oily core, MPE-C increased the droplet-cellular contact area and provoked the cellular recognition of mannose and CpG for enhanced immune activation. We found that MPE-C attracted a large number of APCs to the local site of administration, evidently increasing cellular uptake and activation. Additionally, we observed increased antigen-specific cellular immune responses, with potent anti-tumor effects against both E.G7-OVA and B16-MUCI tumors. Furthermore, MPE-C combined with PD-1 antibodies produced a significant tumor regression, resulting in synergistic increases in anti-tumor effects. Thus, through the strategic loading of mannose, antigens, and CpG, Pickering emulsions could serve as a targeted delivery platform for enhanced multicomponent cancer vaccines.”